<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33473007</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1672-7347</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>Dec</Month><Day>28</Day></PubDate></JournalIssue><Title>Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences</Title><ISOAbbreviation>Zhong Nan Da Xue Xue Bao Yi Xue Ban</ISOAbbreviation></Journal><ArticleTitle>Advances in genetics research in the pathogenesis of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1483</StartPage><EndPage>1489</EndPage><MedlinePgn>1483-1489</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.11817/j.issn.1672-7347.2020.190506</ELocationID><ELocationID EIdType="pii" ValidYN="Y">1672-7347(2020)12-1483-07</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease affecting the upper and lower motor neurons. It is characterized by progressive muscle weakness, atrophy and ultimate death due to dysphagia and dyspnea. There are many causes of ALS, among which the genetic factors show great relevance. Imbalance of protein homeostasis in neurons, prion-like proliferation and propagation of abnormal proteins, mitochondrial dysfunction, glutamate mediated excitotoxicity, and intraneuronal substance transport disorders are recognized as the pathogenesis.The study on gene mutation related to pathogenesis will bridge the molecular and cellular research of ALS, which can deepen the understanding of the occurrence and development of ALS and the role of gene mutation in ALS, and provide new ideas and enlightenment for the treatment of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Xiangya School of Medicine, Central South University, Changsha 410013. wangy0331@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Hang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Xiangya School of Medicine, Central South University, Changsha 410013.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Qiao</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, Changsha 410008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bi</LastName><ForeName>Fangfang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, Changsha 410008, China. fangfangbi@csu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>chi</Language><GrantList CompleteYN="Y"><Grant><GrantID>81571256 and 81760238</GrantID><Agency>the National Natural Science Foundation, China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>&#x808c;&#x840e;&#x7f29;&#x4fa7;&#x7d22;&#x786c;&#x5316;&#x75c7;&#x53d1;&#x75c5;&#x673a;&#x5236;&#x7684;&#x9057;&#x4f20;&#x5b66;&#x7814;&#x7a76;&#x8fdb;&#x5c55;.</VernacularTitle></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhong Nan Da Xue Xue Bao Yi Xue Ban</MedlineTA><NlmUniqueID>101230586</NlmUniqueID><ISSNLinking>1672-7347</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText>&#x808c;&#x840e;&#x7f29;&#x4fa7;&#x7d22;&#x786c;&#x5316;&#x75c7;(amyotrophic lateral sclerosis&#xff0c;ALS)&#x662f;&#x4e00;&#x79cd;&#x7f55;&#x89c1;&#x7684;&#x7d2f;&#x53ca;&#x4e0a;&#x3001;&#x4e0b;&#x8fd0;&#x52a8;&#x795e;&#x7ecf;&#x5143;&#x7684;&#x795e;&#x7ecf;&#x9000;&#x884c;&#x6027;&#x75be;&#x75c5;&#xff0c;&#x4e34;&#x5e8a;&#x8868;&#x73b0;&#x4e3a;&#x808c;&#x8089;&#x8fdb;&#x884c;&#x6027;&#x65e0;&#x529b;&#x3001;&#x840e;&#x7f29;&#xff0c;&#x60a3;&#x8005;&#x6700;&#x7ec8;&#x56e0;&#x541e;&#x54bd;&#x3001;&#x547c;&#x5438;&#x56f0;&#x96be;&#x800c;&#x6b7b;&#x4ea1;&#x3002;ALS&#x7684;&#x75c5;&#x56e0;&#x4f17;&#x591a;&#xff0c;&#x5176;&#x4e2d;&#x9057;&#x4f20;&#x56e0;&#x7d20;&#x76f8;&#x5173;&#x6027;&#x6781;&#x5927;&#x3002;&#x795e;&#x7ecf;&#x5143;&#x4e2d;&#x86cb;&#x767d;&#x8d28;&#x5185;&#x7a33;&#x6001;&#x5931;&#x8861;&#x3001;&#x5f02;&#x5e38;&#x86cb;&#x767d;&#x8d28;&#x7684;&#x670a;&#x75c5;&#x6bd2;&#x6837;&#x589e;&#x6b96;&#x548c;&#x4f20;&#x64ad;&#x3001;&#x7ebf;&#x7c92;&#x4f53;&#x529f;&#x80fd;&#x969c;&#x788d;&#x3001;&#x8c37;&#x6c28;&#x9178;&#x4ecb;&#x5bfc;&#x7684;&#x5174;&#x594b;&#x6027;&#x6bd2;&#x6027;&#x3001;&#x795e;&#x7ecf;&#x5143;&#x5185;&#x7269;&#x8d28;&#x8fd0;&#x8f93;&#x969c;&#x788d;&#x662f;&#x76ee;&#x524d;&#x516c;&#x8ba4;&#x7684;&#x53d1;&#x75c5;&#x673a;&#x5236;&#x3002;&#x5bf9;&#x53d1;&#x75c5;&#x673a;&#x5236;&#x76f8;&#x5173;&#x57fa;&#x56e0;&#x7a81;&#x53d8;&#x7684;&#x7814;&#x7a76;&#x5c06;&#x642d;&#x8d77;ALS&#x5206;&#x5b50;&#x6c34;&#x5e73;&#x7814;&#x7a76;&#x548c;&#x7ec6;&#x80de;&#x6c34;&#x5e73;&#x7814;&#x7a76;&#x7684;&#x6865;&#x6881;&#xff0c;&#x4ece;&#x800c;&#x52a0;&#x6df1;&#x5bf9;ALS&#x7684;&#x53d1;&#x751f;&#x548c;&#x53d1;&#x5c55;&#x53ca;&#x57fa;&#x56e0;&#x7a81;&#x53d8;&#x5728;&#x5176;&#x4e2d;&#x626e;&#x6f14;&#x89d2;&#x8272;&#x7684;&#x4e86;&#x89e3;&#xff0c;&#x5e76;&#x4e3a;&#x75be;&#x75c5;&#x7684;&#x6cbb;&#x7597;&#x63d0;&#x4f9b;&#x65b0;&#x7684;&#x601d;&#x8def;&#x4e0e;&#x542f;&#x793a;&#x3002;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">excitotoxicity</Keyword><Keyword MajorTopicYN="N">gene mutation</Keyword><Keyword MajorTopicYN="N">imbalance of protein homeostasis</Keyword><Keyword MajorTopicYN="N">mitochondrial dysfunction</Keyword><Keyword MajorTopicYN="N">prion-like proliferation and propagation</Keyword><Keyword MajorTopicYN="N">transport disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>21</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33473007</ArticleId><ArticleId IdType="doi">10.11817/j.issn.1672-7347.2020.190506</ArticleId><ArticleId IdType="pii">1672-7347(2020)12-1483-07</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polymenidou M, Cleveland DW. Biological spectrum of amyotrophic lateral sclerosis prions[J]. Cold Spring Harb Perspect Med, 2017, 7(11): a024133.</Citation></Reference><Reference><Citation>Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism[J]. Nature, 2016, 539(7628): 197- 206.</Citation></Reference><Reference><Citation>Maurel C, Dangoumau A, Marouillat S, et al. Causative genes in amyotrophic lateral sclerosis and protein degradation pathways: A link to neurodegeneration[J]. Mol Neurobiol, 2018, 55(8): 6480- 6499.</Citation></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD[J]. Neuron, 2011, 72(2): 257- 268.</Citation></Reference><Reference><Citation>T&#xfc;rk M, Haaker G, Winter L, et al. C9ORF72-ALS: P62- and ubiquitin-aggregation pathology in skeletal muscle[J]. Muscle Nerve, 2014, 50(3): 454- 455.</Citation></Reference><Reference><Citation>Serpente M, Fenoglio C, Cioffi SM, et al. Profiling of ubiquitination pathway genes in peripheral cells from patients with frontotemporal dementia due to C9ORF72 and GRN mutations[J]. Int J Mol Sci, 2015, 16(1): 1385- 1394.</Citation></Reference><Reference><Citation>Al-Sarraj S, King A, Troakes C, et al. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS[J]. Acta Neuropathol, 2011, 122(6): 691- 702.</Citation></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Y&#xe1;&#xf1;ez A, et al. C9orf72 is required for proper macrophage and microglial function in mice[J]. Science, 2016, 351(6279): 1324- 1329.</Citation></Reference><Reference><Citation>Amick J, Ferguson SM. C9orf72: At the intersection of lysosome cell biology and neurodegenerative disease[J]. Traffic, 2017, 18(5): 267- 276.</Citation></Reference><Reference><Citation>Burk K, Pasterkamp RJ. Disrupted neuronal trafficking in amyotrophic lateral sclerosis[J]. Acta Neuropathol, 2019, 137(6): 859- 877.</Citation></Reference><Reference><Citation>Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis[J]. Nature, 1993, 362(6415): 59- 62.</Citation></Reference><Reference><Citation>Nishitoh H, Kadowaki H, Nagai A, et al. ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1[J]. Genes Dev, 2008, 22(11): 1451- 1464.</Citation></Reference><Reference><Citation>Scotter EL, Chen HJ, Shaw CE. TDP-43 proteinopathy and ALS: Insights into disease mechanisms and therapeutic targets[J]. Neurotherapeutics, 2015, 12(2): 352- 363.</Citation></Reference><Reference><Citation>Lin G, Mao D, Bellen HJ. Amyotrophic lateral sclerosis pathogenesis converges on defects in protein homeostasis associated with TDP-43 mislocalization and proteasome-mediated degradation overload[J]. Curr Top Dev Biol, 2017, 121: 111- 171.</Citation></Reference><Reference><Citation>Araki W, Minegishi S, Motoki K, et al. Disease-associated mutations of TDP-43 promote turnover of the protein through the proteasomal pathway[J]. Mol Neurobiol, 2014, 50(3): 1049- 1058.</Citation></Reference><Reference><Citation>Bose JK, Huang CC, Shen CK. Regulation of autophagy by neuropathological protein TDP-43[J]. Biol Chem, 2011, 286(52): 44441- 44448.</Citation></Reference><Reference><Citation>Shenouda M, Zhang AB, Weichert A, et al. Mechanisms associated with TDP-43 neurotoxicity in ALS/FTLD[J]. Adv Neurobiol, 2018, 20: 239- 263.</Citation></Reference><Reference><Citation>Ko HS, Uehara T, Tsuruma K, et al. Ubiquilin interacts with ubiquitylated proteins and proteasome through its ubiquitin-associated and ubiquitin-like domains[J]. FEBS Lett, 2004, 566(1/2/3): 110- 114.</Citation></Reference><Reference><Citation>Lee DY, Brown EJ. Ubiquilins in the crosstalk among proteolytic pathways[J]. Biol Chem, 2012, 393(6): 441- 447.</Citation></Reference><Reference><Citation>Hjerpe R, Bett JS, Keuss MJ, et al. UBQLN2 mediates autophagy-independent protein aggregate clearance by the proteasome[J]. Cell, 2016, 166(4): 935- 949.</Citation></Reference><Reference><Citation>Teyssou E, Chartier L, Amador MD, et al. Novel UBQLN2 mutations linked to amyotrophic lateral sclerosis and atypical hereditary spastic paraplegia phenotype through defective HSP70-mediated proteolysis[J]. Neurobiol Aging, 2017, 58: 239.e11- 239.e20.</Citation></Reference><Reference><Citation>Christianson JC, Ye Y. Cleaning up in the endoplasmic reticulum: ubiquitin in charge[J]. Nat Struct Mol Biol, 2014, 21(4): 325- 335.</Citation></Reference><Reference><Citation>Hasegawa M, Nonaka T, Masuda-Suzukake M. Prion-like mechanisms and potential therapeutic targets in neuro-degenerative disorders[J]. Pharmacol Ther, 2017, 172: 22- 33.</Citation></Reference><Reference><Citation>Chen C, Ding X, Akram N, et al. Fused in sarcoma: properties, self-assembly and correlation with neurodegenerative diseases[J]. Molecules, 2019, 24(8): 1622.</Citation></Reference><Reference><Citation>Madji Hounoum B, Mavel S, Coque E, et al. Wildtype motoneurons, ALS-Linked SOD1 mutation and glutamate profoundly modify astrocyte metabolism and lactate shuttling[J]. Glia, 2017, 65(4): 592- 605.</Citation></Reference><Reference><Citation>Delic V, Kurien C, Cruz J, et al. Discrete mitochondrial aberrations in the spinal cord of sporadic als patients[J]. J Neurosci Res, 2018, 96(8): 1353- 1366.</Citation></Reference><Reference><Citation>Vehvilainen P, Koistinaho J, Gundars G. Mechanisms of mutant SOD1 induced mitochondrial toxicity in amyotrophic lateral sclerosis[J]. Front Cell Neurosci, 2014, 8: 126.</Citation></Reference><Reference><Citation>Hayashi Y, Homma K, Ichijo H. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS[J]. Adv Biol Regul, 2016, 60: 95- 104.</Citation></Reference><Reference><Citation>Fukunaga K, Shinoda Y, Tagashira H. The role of SIGMAR1 gene mutation and mitochondrial dysfunction in amyotrophic lateral sclerosis[J]. J Pharmacol Sci, 2015, 127(1): 36- 41.</Citation></Reference><Reference><Citation>Rosenblum LT, Shamamandri-Markandaiah S, Ghosh B, et al. Mutation of the caspase-3 cleavage site in the astroglial glutamate transporter EAAT2 delays disease progression and extends lifespan in the SOD1-G93A mouse model of ALS[J]. Exp Neurol, 2017, 292: 145- 153.</Citation></Reference><Reference><Citation>Lapucci A, Cavone L, Buonvicino D, et al. Effect of Class II HDAC inhibition on glutamate transporter expression and survival in SOD1-ALS mice[J]. Neurosci Lett, 2017, 656: 120- 125.</Citation></Reference><Reference><Citation>Ohgomori T, Yamasaki R, Takeuchi H, et al. Differential involvement of vesicular and glial glutamate transporters around spinal &#x3b1;-motoneurons in the pathogenesis of SOD1<sup>(G93A)</sup> mouse model of amyotrophic lateral sclerosis[J]. Neuroscience, 2017, 356: 114- 124.</Citation></Reference><Reference><Citation>Xu W, Xu J. C9orf72 dipeptide repeats cause selective neurodegeneration and cell-autonomous excitotoxicity in drosophila glutamatergic neurons[J]. J Neurosci, 2018, 38(35): 7741- 7752.</Citation></Reference><Reference><Citation>Starr A, Sattler R. Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD[J]. Brain Res, 2018, 1693(Pt A): 98- 108.</Citation></Reference><Reference><Citation>Chou CC, Zhang Y, Umoh ME, et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD[J]. Nat Neurosci, 2018, 21(2): 228- 239.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>